Menu ×

HEALTHCARE & PHARMACEUTICAL

Pulmonary Fibrosis Drugs Market Segmentation By Drug (Pirfenidone and Nintedanib) – Global Demand Analysis & Opportunity Outlook 2028

  • Text Size:

Extensive insights into the Growth of Pulmonary Fibrosis Drugs Market amidst COVID-19

Before we witness the stabilization of economic growth in Europe and North America, Asia Pacific is estimated to bounce back progressively with countries such as China, India, South Korea and Japan witnessing more opportunities to recover from the losses sustained during COVID-19.

Being the biggest market in Eastern Europe, Russia is estimated to take the lowest hit, offering a sigh of relief to the businesses operating in the country. Whereas, GCC is estimated to observe low investments due to the sliding prices of crude oil.

We evaluate the strategies and commitment of the Giant Players in the market towards creating products and services that customers value and rely on.

In an attempt to control and eliminate the surge of coronavirus cases and meet the demand for required medical devices along with providing efficient medical services, there is a drastic shift of investments from authoritative bodies towards the healthcare sector. Where the aftermath of this pandemic may take years to be measured, Research Nester estimates notable expansion of e-health, gaming, and media and entertainment industries till the whole situation is contained and the plan of action for the recovery process is determined. There is an estimated probability of the growth in businesses going back a year if the condition is controlled in the next 2-3 months.                                                         Request Insights

Read More
IN THE NEWS
  • On March 18, 2019, AstraZeneca received the Orphan Drug Designation (ODD) for its saracatnib drug from the FDA. Saracatnib is a potential new drug developed for the treatment of idiopathic pulmonary fibrosis (IPF). It is a src kinase inhibitor which regulates various cell functions. The drug has completed Phase 1 development.

Introduction to Pulmonary Fibrosis Drugs

Pulmonary fibrosis is a lung disorder characterized by damage or scarring of the lung tissue. Once the tissue is damaged, it obstructs the passageway for air and thus hinders the normal functioning of the lungs. It is usually caused as a result of certain medical conditions, exposure to toxins, pollutants or radiation or by certain medications.

When the cause of this condition is not known, it is termed as idiopathic pulmonary fibrosis. The common symptoms of this disease include shortness of breath or dyspnea, fatigue, dry cough, weight loss and pain in muscles and joints. Eventually, it may lead to respiratory failure or pulmonary hypertension.

Market Size and Forecast

As per the Pulmonary Fibrosis Foundation, the disease affects about 1 out of 200 adults above the age of 70 years in the United States. Moreover, around 50,000 new cases of pulmonary fibrosis are diagnosed in the country every year.

The pulmonary fibrosis drugs market is anticipated to record a significantly high CAGR over the forecast period, i.e., 2020-2028. The market is segmented by drug and by region, out of which, the drug segment is further bifurcated into pirfenidone and nintedanib. The segment for pirfenidone is anticipated to hold the largest share in the pulmonary fibrosis drugs market on account of increased usage of the drug ever since it received approval by the Food and Drug Administration (FDA). Esbriet is a pirfenidone drug manufactured by Genentech, Inc. and approved by the U.S. FDA in 2014 in the United States. The drug is available as oral dosage in the form of either capsules or tablets. The most common adverse reactions consist of rash, nausea, headache, fatigue, dizziness, insomnia and upper respiratory tract infections. The segment for nintedanib is predicted to grow at a substantial rate as well, owing to the high demand for the drug. Ofev is a nintedanib drug which received FDA approval in 2014 in the United States. This drug, developed by Boehringer Ingelheim International GmbH, is in the form of capsules for oral use. Ofev is a kinase inhibitor indicated for the treatment of idiopathic pulmonary fibrosis (IPF).

Growth Drivers

Risk Factors Associated With Pulmonary Fibrosis to Drive the Market Growth

There are certain risk factors which lead to the occurrence of pulmonary fibrosis. These include geriatric population, smoking, exposure to toxins, cancer treatments along with some genetic factors. According to the National Health Service (NHS) in UK, idiopathic pulmonary fibrosis (IPF) commonly affects people between the ages of 70 and 75 years, and it rarely occurs among people under the age of 50 years. Moreover, it states that about 1 in 20 people with IPF have a family history of the disease. These risk factors are estimated to drive the market growth in coming years. CLICK TO DOWNLOAD SAMPLE REPORT

Increase in Cigarette Smoking Population to Drive the Market Growth

The increasing number of people who smoke is a major concern which results in several diseases of the lungs, including pulmonary fibrosis. According to Centers for Disease Prevention and Control, around 13.7% of all adults, i.e., 34.2 million people were reported to smoke cigarettes in the United States in 2018, out of which, 15.6% were men and 12.0% were women. This is predicted to raise the demand for drugs for pulmonary fibrosis and thereby boost the growth of the market during the forecast period.

Restraints

Limited Availability of Approved Drugs to Restrict the Market Growth

Presently, only a few drugs have been received approval by the FDA and other regulatory bodies for the treatment of pulmonary fibrosis. There are only two approved drugs as of now, pirfenidone and nintedanib. This is estimated to limit the market growth. More research and development in the field is required in order to expand the market size. 

Market Segmentation

Our in-depth analysis of the pulmonary fibrosis drugs market includes the following segments:

By Drug

  • Pirfenidone
  • Nintedanib

By Region

On the basis of regional analysis, the pulmonary fibrosis drugs market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region.

Pulmonary fibrosis drugs market is predicted to grow at the highest rate in the Asia Pacific region on account of growing presence of leading companies involved in research and development activities for the manufacturing of effective drugs. Moreover, the increasing number of patients with pulmonary fibrosis in the region is a major factor estimated to resulting in the market growth over the forecast period. The Lung Foundation of Australia estimates that around 1,250 people in Australia are diagnosed with idiopathic pulmonary fibrosis every year. The market in North America is estimated to hold the leading share in the market as a result of growing research and developments in the area as well as presence of key players in the market in this region.

Pulmonary Fibrosis Drugs Market Graph

The pulmonary fibrosis drugs market is further classified on the basis of region as follows:

  • North America (U.S. & Canada) Market size, Y-O-Y growth & Opportunity Analysis
  • Latin America (Brazil, Mexico, Argentina, Rest of Latin America) Market size, Y-O-Y growth & Opportunity Analysis
  • Europe (U.K., Germany, France, Italy, Spain, Hungary, Belgium, Netherlands & Luxembourg, NORDIC,  Poland, Turkey, Russia, Rest of Europe) Market size, Y-O-Y growth & Opportunity Analysis
  • Asia-Pacific (China, India, Japan, South Korea, Indonesia, Malaysia, Australia, New Zealand, Rest of Asia-Pacific) Market size, Y-O-Y growth & Opportunity Analysis.
  • Middle East and Africa (Israel, GCC (Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman), North Africa, South Africa, Rest of Middle East and Africa) Market size, Y-O-Y growth & Opportunity Analysis

Top Featured Companies Dominating the Market

FREQUENTLY ASKED QUESTIONS


Related Reports


Disclaimer | Privacy Policy | Terms & Conditions

Copyright © 2020 Research Nester. All Rights Reserved